← All trials
NCT05448443
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 21, 2022
- Primary completion
- Dec 31, 2024
- Completion date
- Apr 30, 2025
- First posted
- Jul 7, 2022
- Last posted
- Jul 7, 2022
- Enrollment
- 15
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Istituto Auxologico ItalianoLead sponsor
- Istituto Auxologico ItalianoOverall official - principal investigator
- University of FlorenceCollaborator
- Apnimed, Inc.Collaborator
- STM Pharma PRO srlCollaborator
- VIS Ethic Research SrlCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.